SMITH JASON DREW (General Counsel) sold 5.7% of their position (1.52K shares) of UROGEN PHARMA LTD. on the open market
Open‑market sale worth $19.9K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 9/12/2024ACC: 0001437749-24-029038
Officer· General Counsel
Since Aug 2020
-1.52K
Net shares
Net seller
$19.9K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
3.33K acquired · 4.85K disposed
Non-Derivative Transactions2
Ordinary Shares
Direct
Shares
+3.33K
Price / share
—
Trade value
—
% of position
14.2%
9/9/2024
23.41K→26.75K
Ordinary Shares
Direct
Shares
−1.52K
Price / share
$13.08
Trade value
$19.89K
% of position
5.7%
9/9/2024
26.75K→25.23K
Total
Net shares
+1.81K
Net value
-$19.89K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares Direct | 9/9/2024 | M · Option Exercise | +3.33K | — | — | 14.2% | 23.41K | 26.75K |
| Ordinary Shares Direct | 9/9/2024 | S · Sale | −1.52K | $13.08 | $19.89K | 5.7% | 26.75K | 25.23K |
| Total | +1.81K | -$19.89K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Ordinary Shares
3.33K shares
Shares
−3.33K
Strike price
Held after
6.67K
Exercisable
—
9/9/2024
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Ordinary Shares3.33K shares | 9/9/2024 | M · Option Exercise | −3.33K | — | 6.67K |